Market awaits more direction on Amgen despite positive earnings and guidance
This article was originally published in Scrip
Despite issuing guidance for increased revenue and earnings per share (EPS) for 2013, Amgen's stock price took a small hit in after-hours trading when the company reported 2012 earnings gains on 23 January, but said it wouldn't offer many specifics around its growth strategy beyond currently marketed therapies until February.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.